---
title: "H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290062392.md"
description: "H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cogent Biosciences (COGT) with a $55 price target. The firm highlights Burns' strong track record, including an 18.9% average return. Additionally, Stifel Nicolaus maintained its Buy rating on the stock in June with a lower $45 price target."
datetime: "2026-06-17T13:35:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290062392.md)
  - [en](https://longbridge.com/en/news/290062392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290062392.md)
generator: "portal-rs"
---

# H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Cogent Biosciences today and set a price target of $55.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Burns is a 5-star analyst with an average return of 18.9% and a 45.58% success rate. Burns covers the Healthcare sector, focusing on stocks such as Caribou Biosciences, Cardiff Oncology, and Zymeworks.

In a report released on June 15, Stifel Nicolaus also maintained a Buy rating on the stock with a $45.00 price target.

### Related Stocks

- [COGT.US](https://longbridge.com/en/quote/COGT.US.md)
- [CRBU.US](https://longbridge.com/en/quote/CRBU.US.md)
- [CRDF.US](https://longbridge.com/en/quote/CRDF.US.md)
- [ZYME.US](https://longbridge.com/en/quote/ZYME.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal](https://longbridge.com/en/news/297839428.md)
- [Analyst Reiterates Buy on Cogent Biosciences, Maintains $55 Price Target Amid Late-Stage Pipeline and Strong Cash Position](https://longbridge.com/en/news/296384188.md)
- [Braveheart Bio, Inc. reports Q2 results](https://longbridge.com/en/news/298361396.md)
- [Braveheart Bio, Inc.'s Quiet Period To Expire  on September 15th (NASDAQ:BRVE)](https://longbridge.com/en/news/298264807.md)
- [Cogent Biosciences signs Hovione supply deal for bezuclastinib tablets](https://longbridge.com/en/news/297824674.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**